

## Metadata of the chapter that will be visualized online

Chapter Title	Studying OTUD6B-OTUB1 Protein–Protein Interaction by Low-Throughput GFP-Trap Assays and High-Throughput AlphaScreen Assays
Copyright Year	2021
Copyright Holder	Springer Science+Business Media, LLC, part of Springer Nature
Author	Family Name <b>Weber</b> Particle Given Name <b>Elisabeth</b> Suffix Division Assay Development and Screening Platform Organization Helmholtz Zentrum München Address Neuherberg, Germany
Author	Family Name <b>Schorpp</b> Particle Given Name <b>Kenji</b> Suffix Division Assay Development and Screening Platform Organization Helmholtz Zentrum München Address Neuherberg, Germany
Corresponding Author	Family Name <b>Hadian</b> Particle Given Name <b>Kamyar</b> Suffix Division Assay Development and Screening Platform Organization Helmholtz Zentrum München Address Neuherberg, Germany Email <a href="mailto:kamyar.hadian@helmholtz-muenchen.de">kamyar.hadian@helmholtz-muenchen.de</a>
Abstract	Protein–protein interactions (PPI) are involved in a myriad of cellular processes, and their deregulation can lead to many diseases. One such process is protein ubiquitination that requires an orchestrated action of three key enzymes to add ubiquitin moieties to substrate proteins. Importantly, this process is reversible through deubiquitinating enzymes. Both ubiquitination and deubiquitination require many PPIs that once classified can be utilized to identify small molecule inhibitors counteracting these reactions. Here, we study the protein–protein interaction between the two deubiquitinating enzymes OTUB1 and OTUD6B and report for the first time that both proteins directly interact with each other. We describe the GFP-Trap immunoprecipitation as a cell-based method to analyze the OTUD6B-OTUB1 interaction in the cellular context and the AlphaScreen (amplified luminescent proximity

homogeneous assay) assay as a tool to detect direct interactions and to search for PPI inhibitors.

---

Keywords (separated by '-') Protein-protein interactions - GFP-trap - Immunoprecipitation - AlphaScreen - Ubiquitin - Deubiquitinase - DUB - OTUD6B - OTUB1 - Homogeneous proximity assay

---

## Studying OTUD6B-OTUB1 Protein-Protein Interaction by Low-Throughput GFP-Trap Assays and High-Throughput AlphaScreen Assays

2

3

4

Elisabeth Weber, Kenji Schorpp, and Kamyar Hadian

5

### Abstract

6

Protein-protein interactions (PPI) are involved in a myriad of cellular processes, and their deregulation can lead to many diseases. One such process is protein ubiquitination that requires an orchestrated action of three key enzymes to add ubiquitin moieties to substrate proteins. Importantly, this process is reversible through deubiquitinating enzymes. Both ubiquitination and deubiquitination require many PPIs that once classified can be utilized to identify small molecule inhibitors counteracting these reactions. Here, we study the protein-protein interaction between the two deubiquitinating enzymes OTUB1 and OTUD6B and report for the first time that both proteins directly interact with each other. We describe the GFP-Trap immunoprecipitation as a cell-based method to analyze the OTUD6B-OTUB1 interaction in the cellular context and the AlphaScreen (amplified luminescent proximity homogeneous assay) assay as a tool to detect direct interactions and to search for PPI inhibitors.

7 [AUI](#)

8

9

10

11

12

13

14

15

16

**Key words** Protein-protein interactions, GFP-trap, Immunoprecipitation, AlphaScreen, Ubiquitin, Deubiquitinase, DUB, OTUD6B, OTUB1, Homogeneous proximity assay

17

18

---

## 1 Introduction

19

Cell-based processes use protein interactions or protein networks to positively or negatively regulate cellular pathways. Examples of these processes employing protein-protein interactions (PPIs) are receptor-mediated signaling, transcription and translation, DNA replication, cell death, cell cycle, DNA damage response, and many more. Studying protein interaction networks is key to understanding signaling pathways, development, and diseases. Thus, methodologies detecting and describing PPIs are important tools to explore biological processes. Large-scale techniques such as mass spectrometry uncover cellular protein interactions and larger networks [1]. However, clear information of the direct nature of a PPI is missing in these data sets as two proteins may interact directly or be bridged by, for example, other proteins or nucleic acids. Thus,

20

21

22

23

24

25

26

27

28

29


30

31


32

biochemical assays to verify direct PPIs are needed as parallel approaches to large-scale protein network analyses. The repertoire of biochemical assays include low-throughput assays as well as high-throughput assays [2].

One cellular process that employs many PPIs is protein ubiquitination. Based on the type of protein ubiquitination different cellular events can be controlled, ranging from protein degradation to regulation of signal transduction [3, 4]. The E1 activating enzymes, the E2 conjugating enzymes and the E3 ligases work in a consecutive manner to attach ubiquitin moieties to substrate proteins [4, 5]. The whole cascade undertakes many PPIs among the involved enzymes as well as between the E3 ligases and their substrates [5, 6]. Importantly, ubiquitination is a post-translational modification that is reversible by deubiquitinating (DUB) enzymes [7, 8]. Recent years have shown that there are also protein interactions between E3 ligases and DUBs for tight regulation of cellular ubiquitination [9, 10] as well as between two DUBs [11]. Interaction of two DUBs (OTUD6B (34 kDa) and OTUB1 (31 kDa)) was demonstrated in a study using mass spectrometry analysis. However, the verification of a direct interaction between the two DUBs has not been reported [11]. Here, we use the interaction between OTUD6B and OTUB1 as a showcase to demonstrate how a low-throughput assay (GFP-Trap immunoprecipitation; Fig. 1a) and a high-throughput assay (amplified luminescent proximity homogenous assay—AlphaScreen; Fig. 2a) can be utilized to validate large-scale mass spectrometry data. This can be an essential piece in the puzzle to understand the underlying biology and to develop small molecules altering disease-relevant pathways.



**Fig. 1** (a) The experimental setup for a GFP-Trap immunoprecipitation assay is depicted. ChromoTek GFP-Trap<sup>®</sup> consists of an anti-GFP nanobody/V<sub>H</sub>H coupled to agarose beads, allowing for high-affinity pulldown of GFP-fusion proteins together with its interaction partners. (b) Flag-OTUB1 can be coimmunoprecipitated with GFP-OTUD6B, while no Flag-OTUB1 can be detected when GFP-only is pulled down



**Fig. 2** (a) Sketch of the AlphaScreen assay setup (b) 2.5  $\mu\text{g}$  of the purified GST-OTUD6B and His-OTUB1 proteins were loaded and separated on a 10% SDS gel and stained with Coomassie Brilliant Blue (CBB) G-250 stain. (c) AlphaScreen matrix titration experiment with different protein concentrations of GST-OTUD6B and His-OTUB1 in the range from 300 nM to 0.3 nM. (d) Based on the results in (c) the concentrations of 300 nM GST-OTUD6B and 100 nM His-OTUB1, respectively, were selected for an AlphaScreen assay. 300 nM GST served as a negative control. The experiment was performed as technical replicate ( $n = 3$ , SD)

## 2 Materials

### 2.1 Protein Expression and Purification

1. Prokaryotic expression vector pET-28a(+) (His-tagged proteins). 62
2. Prokaryotic expression vector pGex-4T1 (GST-tagged proteins). 63
3. *E. coli* strain BL21-CodonPlus (DE3) RIPL. 64
4. LB Agar Plate with 100  $\mu\text{g}/\text{mL}$  ampicillin. 65
5. LB Agar Plate with 30  $\mu\text{g}/\text{mL}$  kanamycin. 66

6. LB Medium with 100 µg/mL ampicillin and 25 µg/mL chloramphenicol.	69 70
7. LB Medium with 30 µg/mL kanamycin and 25 µg/mL chloramphenicol.	71 72
8. 1 M isopropyl-β-D-thiogalactopyranoside (IPTG) stock solution in H <sub>2</sub> O.	73 74
9. 20% ethanol for analysis.	75
10. His-Lysis buffer 1: 50 mM Tris pH 8.0, 250 mM NaCl, 50 mM imidazole, 2 mM Tris(2-carboxyethyl)phosphine (TCEP), 1 mM EDTA free Protease Inhibitor Cocktail (PIC), 0.5 mg/mL lysozyme, 250 U benzonase, 2 mM MgCl <sub>2</sub> ( <i>see Notes 1–3</i> ).	76 77 78 79 80
11. His-Lysis buffer 2: 50 mM Tris-HCl, pH 8.0, 250 mM NaCl, 50 mM Imidazole, 2 mM TCEP, 1 mM PIC.	81 82
12. High Salt Wash buffer for His-Tag purification: 50 mM Tris-HCl, pH 8.0, 500 mM NaCl, 50 mM imidazole.	83 84
13. His-Elution buffer: 50 mM Tris-HCl, pH 8.0, 250 mM NaCl, 250 mM Imidazole.	85 86
14. His-Desalting buffer: 50 mM Tris-HCl, pH 8.0, 250 mM NaCl, 2 mM TCEP ( <i>see Note 3</i> ).	87 88
15. Nickel-Sepharose 6 Fast Flow beads.	89
16. GST-Lysis buffer 1: 1× PBS, 400 mM NaCl, 5 mM DTT, 1 mM PIC (EDTA free), 0.5 mg/mL lysozyme, 250 U benzonase, 2 mM MgCl <sub>2</sub> .	90 91 92
17. GST-Lysis buffer 2: 1× PBS, 400 mM NaCl, 5 mM DTT, 1 mM PIC (EDTA free).	93 94
18. GST-Wash buffer: 1× PBS, 400 mM NaCl, 5 mM DTT ( <i>see Note 3</i> ).	95 96
19. Glutathione elution buffer: 50 mM L-glutathione reduced, 1× PBS, 400 mM NaCl, 5 mM DTT ( <i>see Note 3</i> ).	97 98
20. Glutathione-Sepharose 4 Fast Flow beads.	99
21. Polypropylene columns with filter (5 mL) used for gravity-flow chromatography.	100 101
22. Amicon Ultra-15 Centrifugal Filter Unit (15 mL, 3 kDa cutoff).	102 103
23. Benchtop incubator shaker with optional refrigeration.	104
24. BioPhotometer.	105
25. Ultrasonic processor with Sonotrode S2.	106
26. Flexible roller mixer.	107
27. Fast protein liquid chromatography (FPLC) system.	108
28. HiTrap Desalting column 5 mL.	109
29. NanoDrop 2000 spectrophotometer.	110

## 2.2 Immuno-precipitation Using GFP-Traps

1. CO<sub>2</sub> incubator. 11112
2. HEK293T mammalian cell line (ATCC: CRL-2316). 113
3. Dulbecco's Modified Eagle's Medium (DMEM): high Glucose, + L-Glutamine. 114  
115
4. Fetal bovine serum (FBS). 116
5. Penicillin-Streptomycin (Pen-Strep) solution. 117
6. Opti-MEM reduced serum medium. 118
7. DNA transfection reagent (e.g., X-tremeGENE HP). 119
8. Mammalian expression vectors: ~~pEF2-Flag~~, pEGFP-C1. 120
9. 1 × PBS. **Please change to: pEF4-2xFlag** 121
10. GFP-Trap Agarose for immunoprecipitation (ChromoTek). 122
11. RIPA Trap Lysis buffer: 10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.5 mM EDTA, 0.1% SDS, 1% Triton X-100, 2.5 mM MgCl<sub>2</sub>, 1% deoxycholate, 1 mM PIC (EDTA free). 123  
124  
125
12. GFP-Trap wash/dilution buffer: 10 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.5 mM EDTA. 126  
127
13. Benzonase (≥250 U/μL). 128
14. 1 mL syringe with Needle 26 G. 129
15. Rotator, end-over-end. 130
16. 4 × Laemmli protein gel loading buffer, reducing conditions. 131
17. Electrophoresis apparatus. 132
18. Semidry blotter and blotting membrane. 133
19. Primary antibodies: mouse anti-GFP B-2 (Santa Cruz, #sc-9996); mouse anti-Flag M2 (Sigma, # F1804); mouse anti-β-Actin 8H10D10 (Cell Signaling, #3700S). 134  
135  
136
20. Secondary antibodies: donkey anti-mouse HRP. 137
21. Hyperfilm ECL. 138
22. Automatic film processor. 139  
140

## 2.3 "AlphaScreen" Homogeneous Proximity Assay

1. AlphaScreen Glutathione donor beads. 141
2. AlphaScreen Histidine (Nickel Chelate) Detection Kit containing Streptavidin Donor beads and nickel chelate (Ni-NTA) AlphaScreen Acceptor beads. 142  
143  
144
3. AlphaScreen buffer: 1 × PBS, 0.5% BSA, 0.01% Tween 20 (*see Note 4*). 145  
146
4. 384-well OptiPlate, white (PerkinElmer). 147
5. Envision multilabel plate reader including an AlphaScreen module with a filter set for excitation at 680 nm and emission at 520–620 nm. 148  
149  
150  
151

### 3 Methods

152

DNA fragments encoding human full length OTUB1 and OTUD6B were amplified from plasmids by PCR using specific primer pairs in standard PCR protocols and were subsequently subcloned (*see Note 5*).

153

154

155

156

#### 3.1 Protein Expression and Purification Protocols

##### 3.1.1 Recombinant Production and Purification of His-OTUB1

1. Transformation of *E. coli* BL21-DE3-RIPL with pET-28a(+)-OTUB1 using standard procedure and plating on kanamycin plates. 157
2. Preculture #1: inoculate a single transformed clone in 5 mL of LB medium with matched antibiotics and incubate O/N at 37 °C and 180 rpm. 158
3. Preculture #2: next day, inoculate 5 mL of preculture #1 in 50 mL of LB medium with matched antibiotics and incubate O/N at 37 °C and 180 rpm. 159
4. Next day, inoculate 50 mL of preculture #2 in 500 mL of LB medium with matched antibiotics and incubate at 37 °C and 180 rpm. 160
5. Measure OD<sub>600</sub> and incubate up to OD<sub>600</sub> = 0.6; then add another 500 mL of LB medium with matched antibiotics and incubate at 37 °C and 180 rpm. 161
6. At OD<sub>600</sub> = 0.6–0.8 switch to 18 °C, allow the culture to cool down for 20 min and induce protein expression with ~~final~~ IPTG to a final concentration of 1 mM. 162
7. Incubate overnight at 18 °C and 150 rpm. please remove 163
8. Next day, centrifuge culture for 20 min, 4 °C, 2500 × *g*. 164
9. Discard supernatant and use pellet for protein purification. 165
10. Resuspend pellet in 10 mL His-Lysis buffer 1 (*see Notes 6 and 7*). 166
11. Incubate for 20 min at RT and then incubate on ice. 167
12. Sonicate lysate ten times on ice (20 impulses; 30 s resting time in between each sonication cycle) (*see Note 8*). 168
13. Transfer total lysate into prechilled centrifugation tubes; centrifugation at 20,000 × *g*, 50 min, 4 °C. 169
14. Prepare 3 mL Nickel-Sepharose slurry: Wash Sepharose in His-Lysis buffer 2, then spin down for 2 min at 4 °C and 200 × *g*. Repeat this step three times. 170
15. Transfer lysate supernatant into 50 mL reaction tube, fill up with His-Lysis buffer 2 to total 30 mL and add 3 mL pre-washed Nickel-Sepharose slurry. 171
16. Incubate for 2 h at 4 °C with constant inverting. 172

please add "Discard excess supernatant." before "Repeat:

... 200 x g. Discard excess supernatant. Repeat...

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191



	17. Pour bead-lysate mix into propylene column with filter. Allow Sepharose to settle down by gravity flow.	192 193
	18. Wash with 100 mL High Salt Wash buffer for His-Tag purification.	194 195
	19. Let resin run (almost) dry.	196
	20. Elute in five steps with His-Elution buffer (1 mL each) into 15 mL Concentrator tubes.	197 198
	21. Concentrate to 1 mL total.	199
	22. Prepare HiTrap Desalting 5 mL column by washing with EtOH, H <sub>2</sub> O, and His-Desalting buffer (3 column volumes each = 15 mL) on a chromatography system.	200 201 202
	23. Desalt proteins on a chromatography system in His-Desalting buffer.	203 204
	24. Collect main peak fraction and measure protein concentration and DNA/RNA contamination.	205 206
	25. Aliquot and snap-freeze protein samples in liquid nitrogen and store at -80 °C ( <i>see Note 9</i> ).	207 208 209
3.1.2 Recombinant Production and Purification of GST-OTUD6B	1. Transformation of <i>E. coli</i> BL21-DE3-RIPL with pGex-4T1-OTUD6B using standard procedure and plating on ampicillin plates.	210 211 212
	2. Preculture #1: inoculate a single transformed clone in 5 mL of LB medium with matched antibiotics and incubate O/N at 37 °C and 180 rpm.	213 214 215
	3. Preculture #2: next day, inoculate 5 mL preculture #1 in 50 mL of LB medium with matched antibiotics and incubate O/N at 37 °C and 180 rpm.	216 217 218
	4. Next day, inoculate 50 mL of preculture #2 in 500 mL of LB medium with matched antibiotics and incubate at 37 °C and 180 rpm.	219 220 221
	5. Measure OD <sub>600</sub> and incubate up to OD <sub>600</sub> = 0.6; then add another 500 mL of LB medium with matched antibiotics and incubate at 37 °C and 180 rpm.	222 223 224
	6. At OD <sub>600</sub> = 0.6–0.8 switch to 18 °C, allow the culture to cool down for 20 min and induce protein expression with final 1 mM IPTG.	225 226 227
	7. Incubate O/N at 18 °C and 150 rpm.	228
	8. Next day, centrifuge for 20 min, 4 °C, 2500 × <i>g</i> .	229
	9. Discard supernatant and use pellet for protein purification.	230
	10. Resuspend pellet in 10 mL GST-Lysis buffer 1 ( <i>see Notes 6 and 7</i> ).	231 232
	11. Incubate for 20 min at RT and then incubate on ice.	233

12. Sonicate lysate ten times on ice (20 impulses; 30 s resting time in between each sonication cycle) (*see Note 8*). 234  
235
13. Transfer total lysate into prechilled centrifugation tubes; centrifugation at  $20,000 \times g$ , 50 min, 4 °C. 236  
237
14. Prepare 3 mL glutathione–Sepharose slurry: Wash Sepharose in GST-Lysis buffer 2, then spin down for 2 min at 4 °C and **200 × g. Repeat** this step three times. 238  
239  
240
15. Transfer lysate supernatant into 50 mL reaction tube, fill up with GST-Lysis buffer 2 to total 30 mL and add 3 mL pre-washed glutathione–Sepharose slurry. 241  
242  
243
16. Incubate for 2 h at 4 °C with constant inverting. 244
17. Pour bead–lysate mix into propylene-column with filter. Allow Sepharose to settle down by gravity flow. 245  
246
18. Wash with 100 mL GST-Wash buffer. 247
19. Let resin run (almost) dry. 248
20. Elute in five steps in Glutathione Elution Buffer (1 mL each) into 15 mL Concentrator tubes. 249  
250
21. Concentrate to 1 mL total. 251
22. Prepare HiTrap Desalting 5 mL column by washing in EtOH, H<sub>2</sub>O and GST-Wash buffer (3 column volumes each = 15 mL) on a chromatography system. 252  
253  
254
23. Desalt proteins on chromatography system in GST-Wash buffer. 255  
256
24. Collect main peak fraction and measure protein concentration and DNA/RNA contamination. 257  
258
25. Aliquot and snap-freeze protein samples in liquid nitrogen and store at –80 °C (*see Note 9*). 259  
260  
261

### 3.2 GFP-Trap Immunoprecipitation

#### 3.2.1 Seeding of Cells and Transfection

1. Seed HEK293T cells in  $2 \times 10$  cm cell culture dishes with a density of  $2 \times 10^6$  cells in 10 mL DMEM medium + 10% FBS + 1% Pen-Strep. One dish serves as a GFP-control sample, the other as the actual PPI samples (*see Note 10*). Allow cells to attach overnight by culturing cells in an incubator at 37 °C, 5% CO<sub>2</sub> in a H<sub>2</sub>O saturated atmosphere. 262  
263  
264  
265  
266  
267
2. The next day, perform cell transfection with the following plasmids: pEGFP-C1-OTUD6B + pEF4-2×Flag-OTUB1 and as a control pEGFP-C1-Empty + pEF4-2×Flag-OTUB1. 268  
269  
270
3. Prepare a transfection mix for the control sample: combine 500 μL Opti-MEM, 1 μg ~~pEGFP-C1-Empty~~, 2 μg ~~pEF2-×Flag-OTUB1~~ and briefly vortex the solution (*see Note 11*). 271  
272  
273
4. Add 9 μL DNA transfection reagent X-tremeGene HP and briefly vortex (*see Note 12*). 274  
275
7. Incubate for 10–20 min at room temperature. 276

please add “Discard excess supernatant.” before “Repeat:

... 200 x g. Discard excess supernatant. Repeat...

please change to:  
pEE4-2xFlag-OTUB1

please change to:  
pEGFP-C1-Empty

please change to:  
pEE4-2xFlag-OTUB1

8. Prepare a transfection mix for the Heterodimer sample: combine 500  $\mu$ L Opti-MEM, 2  $\mu$ g ~~pEGFP-C1-OTUD6B~~, 2  $\mu$ g ~~pEF2-x-Flag-OTUB1~~ and briefly vortex (*see Note 11*). 277-279
9. Add 12  $\mu$ L DNA transfection reagent X-tremeGene HP and briefly vortex (*see Note 12*). 280-281
10. Incubate for 10–20 min at room temperature. ~~pEGFP-C1-OTUD6B~~ 282
11. Add transfection mix dropwise on cells and incubate for 48 h at 37 °C, 5% CO<sub>2</sub>. 283-284

please change to:

### 3.2.2 Harvesting the Cells

1. Aspirate medium and wash cells carefully with ice-cold 1 $\times$  PBS. 286
2. Aspirate PBS completely. 287
3. Lyse the cells with 200  $\mu$ L ice-cold RIPA-Trap lysis buffer and scrape cells from dish. 288-289
4. Transfer into precooled 1.5 mL reaction tube. 290
5. Add 125 U benzonase to each sample (*see Note 6*). 291
6. Lyse each sample ten times with a 26G needle and 1 mL syringe. 292-293
7. Incubate for 20 min at 4 °C and rotate end-over-end. 294
8. Centrifuge samples at 20,000  $\times g$  for 10 min at 4 °C to clear cell lysates from debris. 295-296
9. Transfer supernatant into new precooled 1.5 mL reaction tubes. 297-298
10. Add 300  $\mu$ L GFP-Trap Wash/Dilution buffer to each sample to achieve a final volume of 500  $\mu$ L per sample. 299-300
11. Transfer ~~60~~  $\mu$ L of total cell lysate to 20  $\mu$ L 4 $\times$  protein loading buffer. **please change to: 50  $\mu$ L** 301-302
12. Boil the sample for 5 min at 95 °C. Store the sample at –20 °C until performance of SDS-PAGE. 303-304

### 3.2.3 Bead Equilibration of GFP-Trap-Agarose

1. ~~Equilibrate GFP-Trap Agarose beads with 15  $\mu$ L bead slurry and 500  $\mu$ L GFP-Trap Wash/Dilution buffer.~~ 306-307
2. Mix the solution by inverting. 308
3. Centrifuge beads at 2500  $\times g$  for 2 min at 4 °C. 309
4. Discard excess supernatant (do not dry beads completely). 310
5. Repeat the washing step twice. 311-312

### 3.2.4 GFP-Trap (Binding, Washing and Elution)

1. Add 15  $\mu$ L equilibrated GFP-Trap Agarose beads to each cell lysate to bind proteins. 313-314
2. Rotate end-over-end for 1.5 h at 4 °C. 315
3. Centrifuge at 2500  $\times g$  for 2 min at 4 °C and discard supernatant. 316-317

Please change to:

Equilibrate 15  $\mu$ L slurry of GFP-Trap Agarose beads with 500  $\mu$ L GFP-Trap Wash/Dilution buffer per sample

4. Wash beads by adding 500  $\mu\text{L}$  GFP-Trap Wash/dilution buffer per sample and mix by inverting. 318  
319
5. Centrifuge at  $2500 \times g$  for 2 min at 4  $^{\circ}\text{C}$ . 320
6. Completely discard supernatant and repeat washing step twice. 321  
After final wash, completely aspirate supernatant from beads. 322  
Be careful not to aspirate beads (*see Note 13*). 323
7. Elute immunocomplexes from GFP-Trap Agarose beads by 324  
addition of 50  $\mu\text{L}$  of  $2\times$  protein loading buffer. 325
8. Boil samples at 95  $^{\circ}\text{C}$  for 5 min. 326
9. Centrifuge at  $20,000 \times g$  for 3 min. 327
10. Perform SDS-PAGE and Western blot [12, 13]. Data analysis 328  
(*see Fig. 1b*) revealed that there is an interaction between 329  
OTUD6B and OTUB1, thereby confirming previously pub- 330  
lished large-scale mass spectrometry data [11]. 331  
332

**3.3 “AlphaScreen”  
Homogeneous  
Proximity Assay**

**3.3.1 AlphaScreen Matrix  
Titration Experiment**

In order to identify the optimal protein concentration for the PPI (robust signal with minimal protein concentration), a matrix titration experiments needs to be performed in accordance with the manufacturer’s protocol (PerkinElmer) (*see Note 14*). 333  
334  
335  
336

1. Perform all dilution steps in AlphaScreen buffer. 337
2. Prepare 200  $\mu\text{L}$  of  $4\times$  working solution (1.2  $\mu\text{M}$ ) of each 338  
protein in the AlphaScreen buffer (*see Note 15*). 339
3. Subsequently, prepare a serial dilution of the 1.2  $\mu\text{M}$  stock 340  
(400, 120, 40, 12, 4, 1.2 nM). 341
4. The assay is done in white 384-well microtiter plates with a final 342  
volume of 40  $\mu\text{L}$  per well (*see Note 16*). 343
5. Add 10  $\mu\text{L}$  of  $4\times$  concentrated GST-OTUD6B (1.2  $\mu\text{M}$ ; 344  
400 nM; 120 nM; 40 nM; 12 nM; 4 nM; 1.2 nM; 0 nM) 345  
into a microtiter plate (each 8-times column-wise). 346
6. Add 10  $\mu\text{L}$  of  $4\times$  concentrated His-OTUB1 (1.2  $\mu\text{M}$ , 400 nM, 347  
120 nM, 40 nM, 12 nM, 4 nM, 1.2 nM, and 0 nM) into the 348  
microtiter plate (each 8-times row-wise) (*see Fig. 2c*). 349
7. Incubate for 1 h at room temperature. 350
8. Prepare 1.5 mL  $2\times$  working solution with AlphaScreen gluta- 351  
thione donor beads (40  $\mu\text{g}/\text{mL}$ ) and AlphaScreen  $\text{Ni}^{2+}$ -NTA 352  
acceptor beads (40  $\mu\text{g}/\text{mL}$ ) (*see Note 17*). 353
9. Immediately after preparation, add 20  $\mu\text{L}$  of the AlphaScreen 354  
bead mix to each well. Final AlphaScreen bead concentration is 355  
20  $\mu\text{g}/\text{mL}$  (*see Note 15*). 356
10. Incubate for 1 h at room temperature in the dark or in dimmed 357  
light (*see Note 18*). 358
11. Analyze the assay using a multilabel plate reader (settings: laser 359  
excitation at 680 nm, emission at 520–620 nm). Based on this 360  
result, we conclude that there is a direct protein–protein 361

interaction between OTUD6B and OTUB1. The optimal concentration for AlphaScreen appears to be 300 nM of GST-OTUD6B and 100 nM His-OTUB1.

### 3.3.2 AlphaScreen PPI Assay at Defined Concentration

1. Chose the optimal concentration for the protein pair from the matrix titration experiment (*see* Subheading 3.3.1). Here, the combination of 300 nM GST-OTUD6B with 100 nM His-OTUB1 results in a robust AlphaScreen signal (Fig. 2c), while the proteins alone without their corresponding binding partner show a markedly reduced signal (background).
2. Include a tag alone control (GST-alone in this case) (Fig. 2d) when performing the assay (*see* Note 19).
3. Perform the assay in white 384-well microtiter plates with a final volume of 40  $\mu$ L per well (*see* Note 16).
4. Add 10  $\mu$ L of 4 $\times$  concentrated GST-tagged proteins (GST-OTUD6B or GST) (each 1.2  $\mu$ M) into a microtiter plate.
5. Add 10  $\mu$ L of 4 $\times$  concentrated His-OTUB1 (400 nM) into the same wells of the microtiter plate.
6. OPTIONAL: add an inhibitory compound dissolved in DMSO at the desired concentration using a 1:100 dilution (e.g., final 10  $\mu$ M = 0.2  $\mu$ L of 2 mM solution) (*see* Notes 20 and 21).
7. Incubate for 1 h at room temperature.
8. Add 20  $\mu$ L of a freshly prepared 2 $\times$  solution with AlphaScreen glutathione donor beads (40  $\mu$ g/mL) and AlphaScreen Ni<sup>2+</sup>-NTA acceptor beads (40  $\mu$ g/mL) (*see* Notes 15 and 17).
9. Incubate for 1 h at room temperature in the dark or in dimmed light (*see* Note 18).
10. Analyze the assay using a multilabel plate reader (settings: laser excitation at 680 nm, emission at 520–620 nm).

---

## 4 Notes

1. His-OTUB1: All buffers used for His-tag purification need to be without EDTA. This includes buffers for lysing cells as well as purification buffers. Protease inhibitor supplements should be without EDTA.
2. TCEP is the preferred reducing agent for His-Purification (Ni-Sepharose) as it does not reduce nickel. In contrast, DTT reduces Nickel.
3. Buffers containing DTT (e.g., GST-Lysis Buffer for purification of GST-tagged OTUD6B) and buffers with TCEP (for purification of His-tagged proteins) should be prepared fresh every time; TCEP is generally slightly more stable than DTT.

4. Use protease free, fatty acid free, essentially globulin free Bovine Serum Albumin (BSA) with purity  $\geq 98\%$ . 404  
405
5. Vectors for GFP-Trap immunoprecipitation: pEGFP-C1 (N-terminal GFP-Tag): **GFP-OTUD6B** = pEGFP-C1-OTUD6B; pEF4-2 $\times$ Flag (N-terminal Flag-Tag): **Flag-OTUB1** = pEF4-2 $\times$ Flag-OTUB1. Vectors for AlphaScreen assay: pGex-4T1 (N-terminal GST-Tag): **GST-OTUD6B** = pGex-4T1-OTUD6B; pET-28a(+) (N-terminal His<sub>6</sub>-Tag): **His-OTUB1** = pET-28a(+)-OTUB1. 406  
407  
408  
409  
410  
411  
412
6. Addition of benzonase helps to reduce DNA and RNA impurification. 413  
414
7. Mg<sup>2+</sup> (1–2 mM) is required for benzonase enzyme activity. 415
8. During the process of sonication, be careful that the lysate does not heat up too much. This process needs to be done on ice and with intervals of sonication and chilling on ice to guarantee optimal protein quality. 416  
417  
418  
419
9. Aliquot purified proteins and snap-freeze in liquid nitrogen prior to long-term storage at  $-80\text{ }^{\circ}\text{C}$ . Prepare small aliquots to avoid multiple freeze and thaw cycles of recombinant proteins. 420  
421  
422  
423
10. A nonbinding Tag-alone control should always be included to identify unspecific binding effects: GFP-alone. 424  
425
11. In order to prepare transfection complexes using XtremeGene HP it is crucial to prepare the complexes in serum-free media (e.g., Opti-MEM), as serum can inhibit the formation of these complexes and thereby reduce transfection efficiency. 426  
427  
428  
429
12. To achieve low cytotoxicity and high transfection efficiency it is often helpful to test the appropriate  $\mu\text{g DNA}:\mu\text{L}$  transfection reagent ratio. Here, 1  $\mu\text{g DNA}:3\ \mu\text{L XtremeGene HP}$  works best. **Please change to "... DNA: $\mu\text{L}$  ..."** 430  
431  
432  
433
13. To completely dry the GFP-Trap Agarose beads after the final wash, it is crucial not to accidentally lose the beads. We therefore recommend using tips with flattened head that allow complete removal of buffer (e.g., Corning CLS4185-400EA). 434  
435  
436  
437
14. When working with the AlphaScreen technology, the hook effect needs to be considered. This effect describes the fact that too much of the proteins can reduce the signal. 438  
439  
440
15. Both the protein solutions and the AlphaScreen bead mix must be freshly prepared on ice and used immediately to avoid increased background signals. 441  
442  
443
16. When pipetting the different solutions into the 384-well plate, try to avoid air bubbles. Reverse pipetting can help here. 444  
445
17. There are beads covered with Glutathione or an anti-GST antibody to detect the GST-tagged protein. Similarly, there are beads coated with Ni<sup>2+</sup>-NTA or an anti-His-Tag antibody 446  
447  
448

- to detect His-tagged proteins. Researchers can consider all variants for their research. In some cases, one variant might work superior to the other.
18. AlphaScreen assays should always be carried out in the dark/in dimmed light surrounding to ensure no bleaching of the beads due to photosensitivity.
  19. A nonbinding Tag-alone control should always be included to identify unspecific binding effects: GST-alone.
  20. When using the AlphaScreen technology for testing of inhibitory compounds or high-throughput screening of small molecule libraries, it is important to be aware that many compounds interfere with the underlying chemistry. These compounds will generate false positive hits that need to be eliminated from the hit list. Chemoinformatics filters can help identify these frequent hitters [14–16].
  21. The DMSO concentration of dissolved compounds should be kept below 1%, ideally below 0.5% as DMSO can affect the proteins as well as the AlphaScreen technology.

---

## Acknowledgments

We thank Stefanie Brandner for excellent technical assistance.

## References

1. Aebersold R, Mann M (2016) Mass-spectrometric exploration of proteome structure and function. *Nature* 537 (7620):347–355. <https://doi.org/10.1038/nature19949>
2. Gul S, Hadian K (2014) Protein-protein interaction modulator drug discovery: past efforts and future opportunities using a rich source of low- and high-throughput screening assays. *Expert Opin Drug Discov* 9(12):1393–1404. <https://doi.org/10.1517/17460441.2014.954544>
3. Komander D, Rape M (2012) The ubiquitin code. *Annu Rev Biochem* 81:203–229. <https://doi.org/10.1146/annurev-biochem-060310-170328>
4. Oh E, Akopian D, Rape M (2018) Principles of ubiquitin-dependent signaling. *Annu Rev Cell Dev Biol* 34:137–162. <https://doi.org/10.1146/annurev-cellbio-100617-062802>
5. Husnjak K, Dikic I (2012) Ubiquitin-binding proteins: decoders of ubiquitin-mediated cellular functions. *Annu Rev Biochem* 81:291–322. <https://doi.org/10.1146/annurev-biochem-051810-094654>
6. Brenke JK, Popowicz GM, Schorpp K, Rothenaigner I, Roesner M, Meininger I, Kalinski C, Ringelstetter L, R'Kyek O, Jurjens G, Vincendeau M, Plettenburg O, Sattler M, Krappmann D, Hadian K (2018) Targeting TRAF6 E3 ligase activity with a small-molecule inhibitor combats autoimmunity. *J Biol Chem* 293(34):13191–13203. <https://doi.org/10.1074/jbc.RA118.002649>
7. Clague MJ, Urbe S, Komander D (2019) Breaking the chains: deubiquitylating enzyme specificity begets function. *Nat Rev Mol Cell Biol* 20(6):338–352. <https://doi.org/10.1038/s41580-019-0099-1>
8. Mevissen TET, Komander D (2017) Mechanisms of deubiquitinase specificity and regulation. *Annu Rev Biochem* 86:159–192. <https://doi.org/10.1146/annurev-biochem-061516-044916>
9. Elliott PR, Nielsen SV, Marco-Casanova P, Fiil BK, Keusekotten K, Mailand N, Freund SM, Gyrd-Hansen M, Komander D (2014) Molecular basis and regulation of OTULIN-LUBAC interaction. *Mol Cell* 54(3):335–348. <https://doi.org/10.1016/j.molcel.2014.03.018>

- 522 10. Lam MH, Urban-Grimal D, Bugnicourt A, 546  
523 Greenblatt JF, Haguenaier-Tsapis R, Emili A 547  
524 (2009) Interaction of the deubiquitinating 548  
525 enzyme Ubp2 and the e3 ligase Rsp5 is 549  
526 required for transporter/receptor sorting in 550  
527 the multivesicular body pathway. *PLoS One* 4 551  
528 (1):e4259. [https://doi.org/10.1371/journal.](https://doi.org/10.1371/journal.pone.0004259) 552  
529 [pone.0004259](https://doi.org/10.1371/journal.pone.0004259) 553
- 530 11. Sowa ME, Bennett EJ, Gygi SP, Harper JW 554  
531 (2009) Defining the human deubiquitinating 555  
532 enzyme interaction landscape. *Cell* 138 556  
533 (2):389–403. [https://doi.org/10.1016/j.cell.](https://doi.org/10.1016/j.cell.2009.04.042) 557  
534 [2009.04.042](https://doi.org/10.1016/j.cell.2009.04.042) 558
- 535 12. Towbin H, Staehelin T, Gordon J (1979) Elec- 559  
536 trophoretic transfer of proteins from polyacryl- 560  
537 amide gels to nitrocellulose sheets: procedure 561  
538 and some applications. *Proc Natl Acad Sci U S* 562  
539 *A* 76(9):4350–4354. [https://doi.org/10.](https://doi.org/10.1073/pnas.76.9.4350) 563  
540 [1073/pnas.76.9.4350](https://doi.org/10.1073/pnas.76.9.4350) 564
- 541 13. Laemmli UK (1970) Cleavage of structural 565  
542 proteins during the assembly of the head of 566  
543 bacteriophage T4. *Nature* 227 567  
544 (5259):680–685. [https://doi.org/10.1038/](https://doi.org/10.1038/227680a0) 568  
545 [227680a0](https://doi.org/10.1038/227680a0) 569
- 546 14. Schorpp K, Rothenaigner I, Salmina E, 547  
548 Reinshagen J, Low T, Brenke JK, 549  
549 Gopalakrishnan J, Tetko IV, Gul S, Hadian K 550  
550 (2014) Identification of small-molecule fre- 551  
551 quent hitters from AlphaScreen high- 552  
552 throughput screens. *J Biomol Screen* 19 553  
553 (5):715–726. [https://doi.org/10.1177/](https://doi.org/10.1177/1087057113516861) 554  
554 [1087057113516861](https://doi.org/10.1177/1087057113516861) 555
- 555 15. Brenke JK, Salmina ES, Ringelstetter L, 556  
556 Dornauer S, Kuzikov M, Rothenaigner I, 557  
557 Schorpp K, Gehler F, Gopalakrishnan J, 558  
558 Kieser A, Gul S, Tetko IV, Hadian K (2016) 559  
559 Identification of small-molecule frequent hit- 560  
560 ters of glutathione S-transferase-glutathione 561  
561 interaction. *J Biomol Screen* 21(6):596–607. 562  
562 [https://doi.org/10.1177/](https://doi.org/10.1177/1087057116639992) 563  
563 [1087057116639992](https://doi.org/10.1177/1087057116639992) 564
- 564 16. Coussens NP, Auld D, Roby P, Walsh J, Baell 565  
565 JB, Kales S, Hadian K, Dahlin JL (2004) 566  
566 Compound-mediated assay interferences in 567  
567 homogenous proximity assays. In: Sittampalam 568  
568 GS, Grossman A, Brimacombe K et al (eds) 569  
569 *Assay guidance manual*. Eli Lilly & Company 570  
570 and the National Center for Advancing Trans- 571  
571 lational Sciences, Bethesda (MD) 572



# Author Queries

Chapter No.: 23      487288\_2\_En

---

Query Refs.	Details Required	Author's response
AU1	Please check whether the author names and affiliations are correct.	author names and affiliations are correct

Uncorrected Proof